A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jan 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pazopanib (Primary) ; Doxorubicin
Indications Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Therapeutic Use
Acronyms EPAZ

27 Dec 2022 Results of post hoc analysis assessing The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome published in the European Journal of Cancer
21 Sep 2021 Results of post-hoc analysis assessing the prognostic impact of frailty, presented at the 46th European Society for Medical Oncology Congress.
24 Aug 2020 Results of a German Intergroup study published in the Journal of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com